



# Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

## SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

### I, Donald Walker

Organisation/Company:

Country:

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

#### 1.1 Employment

Time Period	Start Date	End Date	Name of pharmaceutical company	Function	Title or role within the company	Product Name	Therapeutic indication
Past	01-01-1986	01-03-2010	Pfizer Global R and D	null	null	null	null

#### 1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-03-2019	01-10-2019	Kalvista (via The Research Network)	Cross product related/ general (non product related)	null	null	Consultancy in drug discovery support fo
Past	01-05-2022	01-08-2022	Centessa	Cross product related/ general (non product related)	null	null	Drug metabolism and pharmacokinetics con
Current	01-04-2022	22-03-2023	OccuRx Therapeutics	Cross product related/ general (non product related)	null	null	Drug metabolism and pharmacokinetics con
Current	01-09-2022	22-03-2023	Lario Therapeutics	Cross product related/ general (non product related)	null	null	Drug metabolism and pharmacokinetics con
Current	01-10-2014	22-03-2023	Drugs for Neglected Diseases initiative (DNDi)	Cross product related/ general (non product related)	null	null	Preclinical development strategy
Current	01-09-2019	22-03-2023	Adorx Therapeutics	Cross product related/ general (non product related)	null	null	Drug discovery support for cancer therap
Current	01-10-2021	22-03-2023	Lunac Theapeutics	Cross product related/ general (non product related)	null	null	Consultancy in drug discovery support fo
Current	01-02-	22-03-	Aculeus	Cross product	null	null	Drug metabolism and

	2022	2023	Therapeutics	related/ general (non product related)			pharmacokinetics con
Current	01-05-2022	22-03-2023	Certa Therapeutics	Cross product related/ general (non product related)	null	null	Drug metabolism and pharmacokinetics con
Past	01-07-2015	01-09-2017	Innovimmune	Individual product related	INV_17	Systemic lupus erythematosus	null
Past	01-04-2012	01-12-2015	Medicines for Malaria Venture (MMV)	Individual product related	DSM265, OZ439	Malaria	null
Past	01-05-2012	01-03-2013	Conatus	Individual product related	IDN_6556	Hepatitis C and NASH	null
Past	01-05-2015	01-06-2017	Ziarco Pharma	Individual product related	ZPL_3893787	H4 antagonist for inflammatory skin dise	null
Past	01-06-2017	01-03-2019	Eligochem	Individual product related	Helical AMPs	Bacterial infection	null
Past	01-02-2013	01-02-2017	Piramal (via The Research Network)	Individual product related	P276	Oncology	null

### 1.3 Strategic advisory role

No interest declared

### 1.4 Financial interests

No interest declared

### 1.5 Principal investigator

No interest declared

### 1.6 Investigator

No interest declared

### 1.7 Grant / Funding to organisation /institution

No interest declared

### 1.8 Close family member interest

No interest declared

### 1.9 Repurposing of a medicinal product

No interest declared

### 1.10 Any other interests or facts

I am currently affiliated to The Research Network (TRN), Sandwich, Kent which provides consultation and advice across the pharmaceutical industry and includes the consultancy service provided to Piramal and Kalvista as mentioned in Section 2.2

### 1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## 2.1 Employment

No interest declared

## 2.2 Consultancy

No interest declared

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

No interest declared

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

No interest declared

---

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party <sup>1</sup> any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

*1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.*

Full Name:	Donald Walker
Date:	2023-03-22

For definitions of activities etc, refer to the policy on handling of competing interests.